Clinical trials: Nonalcoholic Fatty Liver
Metabolic Disease, Fatty Liver, Nonalcoholic
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
Given the current increase in the incidence of dyslipidemia and obesity in the general population, there is a strong interest in identifying dietary factors capable of preventing the onset of metabolic diseases or at least…
- Trial name
- NCT05558592
- Testing
- Dietary supplementation with fresh oranges, Balanced Diet without oranges
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET642 in Patients With NASH
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
- Trial name
- NCT04773964
- Testing
- MET642
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Metacrine, Inc.
NAFLD
Probiotics and Microbiota in Bariatric Surgery
This study is a randomized clinical trial with 6 months probiotic supplement vs. placebo treatment and 6 month follow up on 100 NAFLD patients that will undergo sleeve gastrectomy surgery.
- Trial name
- NCT01922830
- Testing
- Bio-25 (Supherb)
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
NAFLD
The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.
- Trial name
- NCT02546609
- Testing
- Leu-Met-Sil 0.5, Leu-Met-Sil 1.0
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- NuSirt Biopharma
Metabolic Syndrome (MetS), Obesity & Overweight
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases
This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and…
- Conditions
- Metabolic Syndrome (MetS), Obesity & Overweight, Cardiovascular Diseases (CVD), Chronic Kidney Disease
- Trial name
- NCT07248371
- Testing
- No intervention
- Where
- Taiwan
- Volunteers
- 6,266 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Alcoholic Steatohepatitis
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT03400163
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
NAFLD, Nonalcoholic Fatty Liver
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United…
- Conditions
- NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT05364684
- Testing
- LUM-201
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Type2 Diabetes, NAFLD
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
High-protein diets have been recently demonstrated to effectively reduce insulin resistance, derangements of the lipid profile and liver fat content in subjects with moderately and severely impaired glucose metabolism and…
- Trial name
- MOCA (NCT04564391)
- Testing
- protein supplement
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
NAFLD
Lifestyle Modification in the Treatment of NAFLD.
The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD/NASH in patients with metabolic syndrome.
- Trial name
- NCT05816915
- Testing
- Cognitive behavioral therapy
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- General University Hospital, Prague
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Liver Diseases, Liver Fat
The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral
The purpose of this study is to promote the diagnosis and awareness of Non-Alcoholic Steatohepatitis (NASH) by linkage of care.
- Conditions
- Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis
- Trial name
- NCT07580482
- Testing
- Best Practice Alert, No Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Non Alcoholic Fatty Liver
Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management
Some studies have shown beneficial results with probiotics on hepatic function of subjects with fatty liver, but significant variability has been noted among probiotic formulations.
- Trial name
- NCT04823676
- Testing
- Probiotic composition
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- AB Biotics, SA
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD).
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
- Trial name
- MASLD (NCT06619808)
- Testing
- Hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jinling Hospital, China
NAFLD, NASH - Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease in HIV Database
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure.
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
- Trial name
- NCT05023044
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.